Journal ArticleDOI
A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development
Reads0
Chats0
TLDR
Cannabidiol (CBD) has been used as an add-on therapy by various regulatory agencies for tuberous sclerosis complex (TSC)-associated seizures based on its short-term efficacy and safety in a pivotal randomized controlled trial as mentioned in this paper .About:
This article is published in Epilepsy & Behavior.The article was published on 2022-02-09. It has received 7 citations till now. The article focuses on the topics: Medicine & Cannabidiol.read more
Citations
More filters
Journal ArticleDOI
Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies
TL;DR: In 2018, the US Food and Drug Administration approved the first phytocannabinoid, cannabidiol (CBD, Epidiolex), which is now indicated for severe seizures associated with three rare forms of developmental and epileptic encephalopathy: Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex as discussed by the authors .
Journal ArticleDOI
Current and future pharmacotherapy options for drug-resistant epilepsy
Samia Elkommos,Marco Mula +1 more
TL;DR: Current and future pharmacotherapy options for the treatment of drug-resistant focal and generalized epilepsies and several molecular targets including inhibition of glycolysis, neuroinflammation and sodium channel inhibition have been identified in animal models.
Journal ArticleDOI
Pharmacotherapeutic management of seizures in patients with Angleman Syndrome
TL;DR: A better understanding of the underlying pathogenesis and the development of molecular therapeutics offer hope for precision therapies for seizures and the treatment landscape may rapidly evolve due to the availability of newer and better tolerated ASMs.
Journal ArticleDOI
Cannabidiol for seizures in tuberous sclerosis complex: Still more questions than answers?
Francesco Brigo,Sasha Olivo +1 more
TL;DR: Samanta et al. as mentioned in this paper provided a scoping review on cannabidiol therapy in tuberous sclerosis: current evidence and perspectives for future development, including clinical efficacy, safety, risk of drug interactions, knowledge gaps and future research have been thoroughly presented and discussed.
Journal ArticleDOI
Behavioral effects induced by the cannabidiol analogs HU-502 and HU-556
TL;DR: In this paper , two cannabidiol analogs (HU-502 and HU-556) were tested in male Swiss mice submitted to the elevated plus maze (EPM), forced swimming test (FST), and amphetamine-induced-prepulse inhibition (PPI) disruption and hyperlocomotion.
References
More filters
Journal ArticleDOI
The tuberous sclerosis complex.
TL;DR: From the Department of Neurology (P.P.N., K.L.C.) and the Division of Medical Genetics (K.B.H.) — both in Philadelphia.
Journal ArticleDOI
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Orrin Devinsky,J. Helen Cross,Linda Laux,Eric D. Marsh,Ian Miller,Rima Nabbout,Ingrid E. Scheffer,Elizabeth A. Thiele,Stephen Wright +8 more
TL;DR: Among patients with the Dravet syndrome, cannabidiol resulted in a greater reduction in convulsive‐seizure frequency than placebo and was associated with higher rates of adverse events.
Journal ArticleDOI
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.
Tiziana Bisogno,Lumir Hanus,Luciano De Petrocellis,Susanna Tchilibon,Datta E. Ponde,Ines Brandi,Aniello Schiano Moriello,John B. Davis,Raphael Mechoulam,Vincenzo Di Marzo +9 more
TL;DR: Results suggest that VR1 receptors, or increased levels of endogenous AEA, might mediate some of the pharmacological effects of CBD and its analogues, and (−)‐5′‐DMH‐CBD represents a valuable candidate for further investigation as inhibitor of AEA uptake and a possible new therapeutic agent.
Journal ArticleDOI
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
Orrin Devinsky,Maria Roberta Cilio,Helen Cross,Javier Fernández-Ruiz,Jacqueline A. French,Charlotte L Hill,Russell Katz,Vincenzo Di Marzo,Didier Jutras-Aswad,William George Notcutt,José Martínez-Orgado,Philip Robson,Brian G. Rohrback,Elizabeth A. Thiele,Benjamin J. Whalley,Daniel Friedman +15 more
TL;DR: CBD bears investigation in epilepsy and other neuropsychiatric disorders, including anxiety, schizophrenia, addiction, and neonatal hypoxic‐ischemic encephalopathy, however, data from well‐powered double‐blind randomized, controlled studies on the efficacy of pure CBD for any disorder is lacking.
Journal ArticleDOI
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes
Luciano De Petrocellis,Alessia Ligresti,Aniello Schiano Moriello,Marco Allarà,Tiziana Bisogno,Stefania Petrosino,Colin Stott,Vincenzo Di Marzo +7 more
TL;DR: CBD and Δ9‐tetrahydrocannabinol interact with transient receptor potential (TRP) channels and enzymes of the endocannabinoid system to explore its role in Cannabidiol-like properties.